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ABSTRACT  
Objectives: Studies have demonstrated an association between congenital heart defects (CHD) 
and postnatal brain abnormalities and neurodevelopmental delay. Recent evidence suggests 
that some of these brain abnormalities are present even before birth. The primary aim of this 
study was to perform a systematic review to quantify the prevalence of prenatal brain 
abnormalities in fetuses with CHD. 
Methods: MEDLINE, EMBASE and The Cochrane Library were searched. Reference lists 
within each article were hand-searched for additional reports. The outcomes included structural 
brain abnormalities (MRI), changes in brain volume (MRI, 3-D volumetric MRI, 3-D ultrasound 
and Phase Contrast Magnetic Resonance), metabolism or maturation (Magnetic Resonance 
Spectroscopy and Phase Contrast Magnetic Resonance) and blood flow (Doppler ultrasound, 
Phase Contrast Magnetic Resonance and 3D Power Doppler ultrasound) in fetuses with CHD. 
Cohort and case–control studies were included. Cases of chromosomal or genetic 
abnormalities, case reports and editorials were excluded. Proportion meta-analysis was used for 
analysis. Between-study heterogeneity was assessed using the I2 test (Registration number: 
CRD42015025546). 
 
Results The search yielded 1,943 citations; and 20 studies were included in the review (n=1175 
cases, 221 in the meta-analysis). Three studies reported data on structural brain abnormalities, 
while data on altered brain volume, metabolism and blood flow were reported in 7, 3 and 14 
studies, respectively. The three studies reporting data on structural brain abnormalities were 
suitable for inclusion in a meta-analysis (221 cases). The prevalence of prenatal structural brain 
abnormalities in fetuses with CHD was 28% (95% CI 18%–40%), similar prevalence in fetuses 
with tetralogy of Fallot of 25% (95% CI 14%-39). These abnormalities included ventriculomegaly 
(commonest), agenesis of the corpus callosum, ventricular bleeding, increased extra-axial 
space, vermian hypoplasia, white matter abnormalities and delayed brain development. Fetuses 
with CHD were more likely, than those without CHD, to have reduced brain volume, delay in 
brain maturation and altered brain circulation, most commonly in the form of reduced middle 
cerebral artery pulsatility index and cerebroplacental ratio. These changes are usually evident in 
the third trimester, but some studies have reported them as early as the second trimester.  
 
Conclusions: In the absence of known major aneuploidy or genetic syndromes, fetuses with 
CHD are at increased risk of brain abnormalities, which are present antenatally.  
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Introduction 
Despite advances in obstetric, neonatal and cardiac care, congenital heart defects (CHD) 
remain the leading cause of infant mortality secondary to birth defects1. The improvement in 
outcomes has led to a shift in focus from cardiac morbidity and mortality towards 
neurodevelopmental outcome2-6. Historically, neurodevelopmental delay in children with CHD 
was attributed to brain injury during their cardiac surgery7-10. However, this assumption may not 
be true. Studies have reported a high prevalence of brain lesions on neuroimaging11-15 and a 
significant risk of neurodevelopmental delay16-18 before cardiac surgery and in those who did not 
undergo cardiac surgery. We reported that the incidence of brain lesions on conventional 
imaging before surgery is 34% in cases of transposition of the great arteries (TGA) and 49% in 
left-sided heart lesions19. Moreover, 40% of these newborns/infants exhibit impaired 
neurodevelopment19. These findings generated animated discussion among fetal medicine 
specialists and pediatric cardiologists, in particular in relation to TGA, in which the surgical 
outcome has been very successful. However, these findings are consistent with those of a 
landmark study investigating the long-term outcome of CHD, where 33% of children 16 years of 
age with TGA who had undergone the arterial switch operation as infants; had brain MRI 
abnormalities and 65% received remedial academic or behavioral services20. 
 
Key questions are whether these brain abnormalities are already present before birth; if so, 
what is the underlying mechanism, and could prenatal intervention alter the outcome. One 
possible explanation for the high incidence of brain abnormalities and neurodevelopmental 
impairment is that these neonates may have suffered the ‘injuries’ post-natally, for example, 
when the arterial duct closed19. Our previous meta-analysis included newborn and infants, but 
not fetuses, in order to avoid clinical heterogeneity. Therefore, we could not investigate the 
prevalence of these abnormalities before birth in fetuses with CHD19. 
 
Compared to postnatal life, fewer studies have investigated prenatal brain development in 
fetuses with CHD21-24. The prevalence of brain abnormalities demonstrated on fetal MRI was 
reported to be as high as 39%22. The primary aim of this study was to perform a systematic 
review to quantify the prevalence of brain abnormalities in fetuses with apparently isolated CHD. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Methods 
 
Protocol, eligibility criteria, information sources and search 
This review was performed according to a protocol designed a priori and recommended for 
systematic reviews and meta-analysis25-27. MEDLINE (1966 - July 2015), EMBASE (1974 - July 
2015) and The Cochrane Library (since inception) including The Cochrane Database of 
Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and The 
Cochrane Central Register of Controlled Trials (CENTRAL) were searched electronically on 
18th November 2014, and updated on 6th  August 2015 utilizing combinations of the relevant 
MeSH terms, key words, and word variants for “congenital heart”, “cardiac”, “neurologic”, “MRI”, 
“ultrasound”, “neuroimaging”, “brain”, “outcome” (Supplementary Table 1). No language 
restrictions were imposed in the search or selection criteria. Reference lists of relevant articles 
and reviews were hand searched for additional reports. The MOOSE guidelines were followed27. 
The study was registered with the PROSPERO database (Registration number: 
CRD42015025546, http://www.crd.york.ac.uk/PROSPERO). 
 
 
Study selection, data collection and data items 
Studies were assessed according to the following criteria: population, outcome, study design, 
gestational age, imaging modality and type of CHD. Studies reporting brain abnormalities or 
changes on neuroimaging in fetuses with CHD were included. Cases were excluded if they 
underwent prenatal cardiac surgical intervention, had other structural abnormalities (apart from 
the heart or the brain) or cases with known genetic/chromosomal anomalies.  
 
All abstracts were reviewed independently by two authors (SB, AK). Agreement about potential 
relevance was reached by consensus, and full text copies of those papers were obtained. The 
same two reviewers independently extracted data regarding study characteristics and the 
outcomes. Inconsistencies were discussed by the reviewers and consensus reached. For those 
articles in which information was not reported but the methodology was such that this 
information would have been recorded initially, the authors were contacted (but no information 
was provided).  If more than one study was published for the same cohort with identical 
endpoints, the report containing the most comprehensive information on the population was 
included to avoid overlapping populations.  
 
The outcomes observed in this systematic review were: 
 
1) Structural brain abnormalities: These include anatomical brain abnormalities, such as 
periventricular leukomalacia and malformation of cortical development. The detection method 
was fetal brain MRI as some of the brain abnormalities can be detected by prenatal MRI but not 
ultrasound. The ascertainment method was postnatal brain imaging or post-mortem examination 
when performed. 
 
2) Changes in brain volume: These include significantly smaller brain volume when compared to 
controls (fetuses without CHD) or the gestational age-expected normal range or progressive 
decline in the brain volume when assessed longitudinally indicating reduced growth rate.  The 
detection methods included fetal brain MRI, 3-D volumetric MRI, 3-D ultrasound and Phase 
Contrast Magnetic Resonance. The ascertainment method, which was rarely reported in the 
studies, was postnatal brain imaging when performed. 
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
3) Changes in brain metabolism or maturation: These included changes in the N-acetylaspartate 
(NAA)/choline, Inositol/Choline or Choline/Creatinine ratios, oxygen saturation (SaO2) of brain 
blood supply or cerebral oxygen consumption (VO2). The detection methods included Magnetic 
Resonance Spectroscopy and Phase Contrast Magnetic Resonance. The ascertainment 
method, which was rarely reported in the studies, was postnatal brain imaging when performed. 
 
4) Changes in brain blood flow: These included changes in the middle cerebral artery (MCA) 
pulsatility index (PI) or resistance index (RI) or their z scores, cerebroplacental ratio (CPR), 
umbilical to cerebral ratio (U/C), blood flow perfusion blood flow perfusion, fractional moving 
blood volume, vascularization index (VI) and flow index (FI). The detection methods included 
Doppler ultrasound, Phase Contrast Magnetic Resonance and 3D Power Doppler ultrasound.   
 
Prospective and retrospective cohort, case-control studies and case series with more than three 
fetuses with CHD were included. Case reports, conference abstracts and editorials were 
excluded. Studies reporting data on changes in head size without associated brain changes 
were excluded to avoid over-interpreting these findings as brain abnormalities. Studies where 
the data on robust outcomes could be extracted were included. 
 
Risk of bias, summary measures and synthesis of the results 
Quality assessment of the included studies was performed using the Strengthening the 
Reporting of Observational Studies in Epidemiology statement criteria27. We used random-effect 
meta-analyses of proportions to combine data on the prevalence of structural brain 
abnormalities in fetuses with CHD28,29. The small number of studies/cases did not permit 
meaningful stratified meta-analyses according to the type of CHD, except for Tetralogy of Fallot 
(TOF). Between-study heterogeneity was assessed using the I2 statistic30. Publication bias was 
explored using funnel plots and was assessed statistically using Egger test (which uses the 
actual values of the effect sizes and their precision, rather than ranks)31. The assessment of the 
potential publication bias was problematic because of the low number of individual studies, 
which strongly limits the reliability of formal tests. Funnel plots displaying the outcome rate from 
individual studies versus their precision (1/standard error) were carried out with an exploratory 
aim. Tests for funnel plot asymmetry were not used when the total number of publications 
included for each outcome was less than ten. In this case, the power of the tests is too low to 
distinguish chance from real asymmetry32. 
 
Statistical analyses were performed using Stats Direct (Version 2.7.8, Stats Direct Ltd, 9 
Bonville Chase, Altrincham, Cheshire WA14 4QA, UK) statistical software.  
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Results 
The search yielded 1,943 citations; of these, 1883 were excluded by review of the title or 
abstract, as they did not meet the selection criteria, contain original data, were not relevant or 
contained postnatal data only (Figure 1). Full manuscripts were retrieved for the remaining 60, 
and a total of 20 studies (n=1175 cases) were included in the review. Three studies reported 
data on structural brain abnormalities, while data on altered brain volume, metabolism and 
blood flow were reported in 7, 3 and 14 studies, respectively (Figure 1). The three studies 
reporting data on structural brain abnormalities were suitable for inclusion in a meta-analysis 
(221 cases)  
 
Structural brain abnormalities in fetuses with CHD  
Table 1 shows the findings of the studies included that reported structural brain abnormalities. 
The fetal brain MRI was performed in the second half of pregnancy, ranging from 18 to 39 
weeks’ gestation. The most commonly reported abnormality was ventriculomegaly (8.6% of the 
fetuses with CHD). Other abnormalities included malformation or delay of cortical development 
(4.5%), vermian hypoplasia (1.4%), agenesis of the corpus callosum (ACC) (8.1%), 
holoprosencephaly (0.5%), cerebellar hypoplasia (0.5%), ventricular bleeding (0.5%), enlarged 
subarachnoid space (1.9%), germinolytic or periventricular cysts (5.1%)22-24. 
 
The pooled prevalence of structural brain abnormalities (Figure 2) was 59/221 (28%, 95% CI 
18-40%, I²=63.8%). As the number of cases in most studies is too small to report their findings 
according to the type of CHD, some studies categorized CHD into groups according to their 
hemodynamic changes. One study classified these brain abnormalities into malformations (such 
as ACC, malformation of cortical development and Dandy Walker malformation), acquired 
lesions (such as periventricular leukomalacia, stroke and white matter injury), and widening of 
the ventricles and/or outer cerebrospinal fluid (CSF) spaces22. Subgroup analysis was possible 
in cases with TOF, where data from two studies could be pooled23,24. The prevalence of 
structural brain abnormalities in fetuses with TOF (Figure 3) was 10/41 (25%, 95% CI 14-39%).  
 
Changes in brain volume in fetuses with CHD 
Table 2 illustrates the findings of the studies included that reported on brain volume changes. 
Neuroimaging was performed using either fetal brain MRI or 3D/4D ultrasound, and was 
performed in the second half of the pregnancy in all of the studies except one, in which the 
ultrasound brain assessment was performed as early as 14 weeks’ gestation33. Of note is that 
this was the only study that did not show a different growth pattern in fetuses with CHD when 
compared with the control group33. Pooling of the data reported in these studies was not 
possible due to the clinical heterogeneity and lack of a consistent method of reporting the data 
quantitatively. All of these studies had a case-control design and most included mixed types of 
CHD, except for two studies reporting data on hypoplastic left heart syndrome (HLHS) and 
TOF23,34. Studies reported a significant delay in cortical gyrification, shallower parieto-occipital, 
cingulate, and calcarine fissures, when compared with controls34,35. 
 
 
Changes in brain metabolism or maturation in fetuses with CHD 
Table 3 shows the findings of the studies that reported on changes in brain metabolism. 
Functional brain MRI was performed in the third trimester21,35,36. Similar to the brain volume 
changes, pooling of the data on altered brain metabolism was not possible due to the clinical 
heterogeneity. However, all three studies were consistent in reporting significantly altered brain 
metabolism and oxygen saturation in fetuses with CHD21,35,36. The reported abnormalities 
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included a change in the N-acetylaspartate/choline, inositol/choline and choline/creatinine 
ratios21,35,36.  
 
Changes in brain blood flow in fetuses with CHD 
Table 4 shows the findings of the studies that reported on changes in brain circulation. 
Circulatory changes were assessed using Doppler ultrasound performed in the second and third 
trimesters, except for one study in which functional MRI was used35--48. The cerebral vessel 
most commonly studied was the middle cerebral artery (MCA), often combined with the 
umbilical artery (UA) Doppler as the cerebroplacental ratio (CPR). As both the MCA and UA 
pulsatility index change with gestational age, some studies adjusted for this potential 
confounding factor using either Z scores or centiles35,37-48. In view of the clinical heterogeneity in 
the gestational age at assessment, vessel examined, variables reported and types of CHD, 
pooling of the data was not attempted. However, The CPR was significantly lower in fetuses 
with CHD when compared to controls in more than half (8/14) of the studies35,37-41,47,48, while the 
MCA Doppler was significantly altered in fetuses with CHD when compared to controls in 10/14 
studies35,37,39,41,43,44-48. 
 
Quality assessment of the included studies 
The quality of the studies is summarized in Figure 4. Among the studies included in this review, 
the title, abstract, background, objectives, study design, assessment methods and the 
interpretation of the studies were appropriately described in 100%. On the other hand, 
explanation of study size (sample size calculation) was reported in none, and flow diagrams to 
describe the study population were rarely used. However, statistical methods were described in 
90% of these studies. The study setting, recruitment period, eligibility, matching criteria, data 
variables and summary of the key findings were adequately described in more than 70%. Efforts 
to address bias and acknowledging the limitations of the study were reported in approximately 
50% of studies (Figure 4).  
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Discussion 
 
Summary of findings 
This meta-analysis suggests that CHD is associated with an unexpectedly high prevalence of 
prenatal structural brain abnormalities, reduced brain volume, delay in brain maturation and 
altered brain circulation. These changes are illustrated on neuroimaging in the third trimester, 
but some may be detected as early as the second trimester.  
 
Interpretation of the findings 
 
1. Are the brain abnormalities present before or after birth? 
The overall prevalence of structural brain abnormalities is increased, but to a slightly lower 
degree than we previously reported in newborns/infants with CHD before cardiac surgery or 
who did not have cardiac surgery19. The brain abnormalities reported here during fetal life are 
similar to those reported after birth, in particular ventriculomegaly, ACC, ventricular bleeding, 
enlarged subarachnoid space and brain cysts19.  
 
Both meta-analyses included observational studies, with their inherent risks of bias and possible 
over- or under-reporting of brain abnormalities in cases with CHD. One main limitation of the 
previous meta-analysis, which we have addressed in the current review, was the inability to 
clarify whether the reported brain abnormalities detected on neuroimaging had occurred before 
or after birth. The fact that the prevalence of brain abnormalities reported in fetuses was slightly 
lower than that reported in newborns with CHD before or without surgery suggests that 
peripartum events are unlikely to be the main contributor. The findings of the current systematic 
review, which was limited to the findings of antenatal neuroimaging, are consistent with those of 
pathological studies49,50.  Almost half of babies with HLHS had associated congenital brain 
abnormalities in pathological studies49,50. We did not include pathological studies in this review, 
in order to avoid clinical heterogeneity.  
 
2. What is the explanation for this association between brain abnormalities and CHD? 
Conventionally, G banded karyotyping was used to exclude aneuploidy. However, compared to 
routine karyotype, up to 6% additional clinically relevant deletions or duplications can be 
diagnosed in fetuses with a structural anomaly using microarray analysis51. In cases with CHD, 
the incremental yield is as high as 16%52. This suggests that undiagnosed chromosomal 
aberrations could explain the reported association with structural brain abnormalities. 
Furthermore, in some of the studies the excluded chromosomal abnormalities were limited to 
22q11 microdeletion, and trisomy 13, 21, and 18. In the study by Mlczoch and colleagues, 
chromosomal analysis was not performed in 31/53 cases22. Similarly, in 37% of cases reported 
by Schellen et al there was no genetic work up23. However, a recent study reported no 
difference in brain size and/or oxygenation between syndromic and non-syndromic fetuses with 
CHD36, which makes a genetic origin of the observed brain changes unlikely.  
An alternative explanation for this association could be altered cerebral circulation in-utero in 
fetuses with CHD35,37-47. This hypothesis is supported by the finding of a higher prevalence of 
brain lesions amongst babies with left-sided heart lesions in postnatal studies, compared to 
cases of TGA19,53,54.  
 
3. Does the association between brain abnormalities and CHD vary according to the type of 
CHD? 
The risk of brain abnormalities detected in neonates/infants before cardiac surgery seems to be 
greatest in left-sided heart lesions, e.g. HLHS19. However, the brain abnormalities and impaired 
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brain growth reported in fetuses with TOF as early as the second trimester question the 
assumption that fetuses with right ventricular outflow tract obstruction are less affected by 
altered cerebral perfusion than fetuses with left-sided heart lesions23. In a recent study, the type 
of the CHD was not significantly associated with the risk of abnormal brain neurodevelopment35, 
and prenatal brain changes and childhood developmental delay have also been demonstrated 
in CHD types that are associated with normal brain perfusion during fetal life41,55. Therefore, 
simply relying on the type of CHD as a predictor of the risk of impaired brain development is not 
likely to be clinically useful, and larger prospective studies are required. 
 
4. How early can brain abnormalities be detected in fetuses with CHD? 
Smaller head size is commonly described in fetuses with CHD35,47. As a small head size per se 
does not necessarily equate to brain abnormalities or neurodevelopmental delay, we have 
excluded the data on small head size unless it was associated with brain abnormalities. These 
brain changes can be detected as early as 25 weeks’ gestation, and as early as 20 weeks in 
TOF23,34. This altered brain development might be already present in affected fetuses as early 
as 20 weeks, and degenerative changes in the developing cortex become increasingly apparent 
during the late third trimester21,34. 
 
Strengths and limitations of the systematic review 
 
The quality of the data available for meta-analysis limits the current study findings. Small 
numbers and selection bias of retrospective reviews were the general drawbacks. With specific 
reference to the type of CHD, the lack of extractable data on clinical sub-groups of CHD and the 
clinical heterogeneity among the studies are likely to have resulted in under- or over-reporting of 
these adverse outcomes.  
Clinical and research implications of the review findings 
 
There is growing evidence indicating a prenatal effect of CHD on brain development, implying 
that postnatal neuroprotective interventions are likely to be of limited value. An important 
question is whether the delay in brain growth, development and maturation result in significant 
neurodevelopmental delay and, if so, whether it might be possible to identify those fetuses at 
increased risk and ultimately improve the postnatal outcome. Firstly, Bayley Scales of Infant and 
Toddler Development (BSID-III) average scores were found to be significantly correlated to total 
brain volume, cingulated fissure depth, inositol/choline and N-acetylaspartate/ choline ratios35. 
Secondly, cerebrovascular resistance is associated with higher neurodevelopmental scores in 
fetuses with single ventricle anomalies56. Thirdly, brain dysmaturation is associated with 
increased susceptibility to white matter injury. Fourthly, these brain changes can potentially be 
detected as early as 25 weeks’ gestations, but more importantly, hemodyamic brain changes 
recorded as early as 20 weeks can identify those fetuses who will manifest delayed brain growth 
and maturation, and ultimately those who will suffer from neurodevelopmental impairment35. A 
more exciting finding recently reported by Sun et al, is a proposed direct link between reduced 
cerebral oxygenation and impaired brain growth in fetuses with CHD, which raises the possibility 
of an improvement of the in utero brain development using maternal oxygen therapy36.  
Based on the findings of this meta-analysis, we would recommend a prospective longitudinal 
study where cases with CHD have brain fetal MRI in the third trimester, and after birth, close 
periodic developmental surveillance follow-up. Despite the fact that the American Heart 
Association recommends periodic developmental surveillance, screening, evaluation, and 
reevaluation throughout childhood in children with CHD57, it is not currently routine to screen for 
brain abnormalities or neurodevelopmental delay in newborns with CHD. The evidence from this 
meta-analysis and other studies calls for a policy which recommends early assessment of these 
cases, starting from fetal life. Finally, the identification of significant brain abnormalities during 
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fetal life might also influence the parents’ decision following antenatal counseling. In response to 
these findings the International society of Ultrasound in Obstetrics and Gynecology (ISUOG) is 
developing a consensus on how these pregnancies should be counseled prenatally, including 
conveying these findings and the limitations of the published literature. 
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Supplementary Table 1. Search strategy using Medline, Embase and The Cochrane Library 
(since inception) including The Cochrane Database of Systematic Reviews (CDSR), Database 
of Abstracts of Reviews of Effects (DARE) and The Cochrane Central Register of Controlled 
Trials (CENTRAL). 
Databases: Embase®,  Embase® Alert,  MEDLINE® 
 
Set# Searched for Results 
S15 s13 or s14 1719 
S14 ((s1 or s2 or s3) and (s4 or s5 or s6) and (s7 or s8 or s9 or s10 or s11)) not 
(animal(yes) or EMB.EXACT("nonhuman")) 
1537 
S13 (s1 or s2 or s3) and (s4 or s5 or s6) and (s7 or s8 or s9 or s10 or s11) and 
human(yes) 
1621 
S12 (s1 or s2 or s3) and (s4 or s5 or s6) and (s7 or s8 or s9 or s10 or s11) 1811 
S11 ti,ab(fetus[*2] or foetus[*2] or fetal[*2] or foetal[*2] or prenatal[*2] or "pre 
natal[*2]" or prepartal[*2] or "pre partal[*2]" or prepartum[*1] or "pre partum[*1]" 
or antenatal[*2] or "ante natal[*2]" or antepartal[*2] or "ante partal[*2]" or 
antepartum[*1] or "ante partum[*1]" or "in utero" or intrauterine or "intra uterine" 
or uterine or preimplant[*6] or "pre implant[*6]" or fetalis or foetalis or 
pregnan[*4] or trimester[*1]) 
1627149 
S10 EMB.EXACT("fetomaternal transfusion") OR EMB.EXACT("intrauterine growth 
retardation") OR EMB.EXACT.EXPLODE("prenatal diagnosis") OR 
EMB.EXACT("prenatal development") OR EMB.EXACT("prenatal stress") OR 
EMB.EXACT("prenatal injury") OR EMB.EXACT("prenatal disorder") OR 
EMB.EXACT("prenatal period") OR EMB.EXACT("prenatal drug exposure") OR 
EMB.EXACT("prenatal exposure") OR EMB.EXACT("prenatal growth") OR 
EMB.EXACT("prenatal mortality") OR EMB.EXACT("prenatal screening") OR 
EMB.EXACT("prenatal care") OR EMB.EXACT.EXPLODE("pregnancy") OR 
EMB.EXACT.EXPLODE("multiple pregnancy") OR EMB.EXACT("prolonged 
pregnancy") OR EMB.EXACT("pregnancy complication") OR EMB.EXACT("high 
risk pregnancy") OR EMB.EXACT.EXPLODE("ectopic pregnancy") OR 
EMB.EXACT("pregnancy disorder") OR EMB.EXACT("pregnancy outcome") OR 
EMB.EXACT("pregnancy rate") OR EMB.EXACT("early pregnancy factor") OR 
EMB.EXACT("pregnant woman") 
885654 
S9 EMB.EXACT("fetus") OR EMB.EXACT("fetus outcome") OR 
EMB.EXACT.EXPLODE("fetus maturity") OR EMB.EXACT.EXPLODE("fetus 
development") OR EMB.EXACT("fetus hypoxia") OR EMB.EXACT("fetus 
297644 
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disease") OR EMB.EXACT("fetus distress") OR EMB.EXACT("fetus 
malformation") OR EMB.EXACT.EXPLODE("fetus function test") OR 
EMB.EXACT.EXPLODE("fetus echography") OR EMB.EXACT.EXPLODE("fetus 
control") OR EMB.EXACT("fetus heart rate") OR EMB.EXACT("fetus 
monitoring") OR EMB.EXACT("fetus blood") OR EMB.EXACT("fetus heart") OR 
EMB.EXACT.EXPLODE("fetus (anatomy)") OR EMB.EXACT("fetus circulation") 
OR EMB.EXACT("fetus growth") OR EMB.EXACT("fetus mortality") OR 
EMB.EXACT("fetus movement") OR EMB.EXACT("fetus resorption") OR 
EMB.EXACT("fetus death") OR EMB.EXACT("fetus wastage") OR 
EMB.EXACT("fetus risk") OR EMB.EXACT("fetus weight") OR 
EMB.EXACT("fetal hemorrhage") OR EMB.EXACT("fetotoxicity") 
S8 MESH.EXACT.EXPLODE("Prenatal Diagnosis") OR 
MESH.EXACT.EXPLODE("Ultrasonography, Prenatal") OR 
MESH.EXACT("Prenatal Exposure Delayed Effects") OR 
MESH.EXACT("Prenatal Injuries") OR MESH.EXACT("Prenatal Care") OR 
MESH.EXACT("Uterine Monitoring") OR MESH.EXACT("Pregnancy") OR 
MESH.EXACT("Pregnancy Complications") OR MESH.EXACT("Pregnancy 
Rate") OR MESH.EXACT.EXPLODE("Pregnancy Trimesters") OR 
MESH.EXACT("Pregnancy, High-Risk") OR 
MESH.EXACT.EXPLODE("Pregnancy, Multiple") OR 
MESH.EXACT("Pregnancy, Heterotopic") OR MESH.EXACT("Pregnancy, 
Prolonged") OR MESH.EXACT.EXPLODE("Pregnancy, Ectopic") OR 
MESH.EXACT("Pregnant Women") OR MESH.EXACT("Pregnancy, 
Unplanned") OR MESH.EXACT("Pregnancy, Unwanted") 
715455 
S7 MESH.EXACT.EXPLODE("Fetal Monitoring") OR 
MESH.EXACT.EXPLODE("Fetal Heart") OR MESH.EXACT.EXPLODE("Fetus") 
OR MESH.EXACT("Fetal Diseases") OR MESH.EXACT("Fetal Viability") OR 
MESH.EXACT("Fetal Movement") OR MESH.EXACT("Fetal Development") OR 
MESH.EXACT("Fetal Weight") OR MESH.EXACT("Fetal Organ Maturity") OR 
MESH.EXACT("Fetal Blood") OR MESH.EXACT("Fetal Death") OR 
MESH.EXACT("Fetal Resorption") OR MESH.EXACT("Fetal Distress") OR 
MESH.EXACT("Fetal Growth Retardation") OR MESH.EXACT("Fetal Hypoxia") 
OR MESH.EXACT("Fetal Mortality") OR MESH.EXACT("Heart Rate, Fetal") OR 
MESH.EXACT("Maternal-Fetal Exchange") 
213787 
S6 ti,ab((brain* or cranial or cerebral or cerebell* or craniocerebral or intracerebral 
or intracranial) near/5 (malform* or abnormal* or anomaly or anomalies or 
defect* or dysfunction* or develop[*5] or maturation* or maturity or impair* or 
delay* or function* or size or volume or growth or structur[*2] or microstructur[*2] 
or bleed* or microbleed* or hemorrhag* or microhemorrhag* or haemorrhag* or 
microhaemorrhag* or impedance or damage* or injury or injuries or trauma*)) 
721929 
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S5 EMB.EXACT("brain malformation") OR EMB.EXACT("brain development") OR 
EMB.EXACT("nervous system development") OR EMB.EXACT("brain 
maturation") OR EMB.EXACT("brain dysfunction") OR EMB.EXACT("brain 
function") OR EMB.EXACT("brain size") OR EMB.EXACT("brain growth") OR 
EMB.EXACT.EXPLODE("brain metabolism") OR EMB.EXACT.EXPLODE("brain 
hemorrhage") OR EMB.EXACT("brain damage") OR EMB.EXACT("traumatic 
brain injury") OR EMB.EXACT("cerebellum injury") OR EMB.EXACT("brain 
injury") 
372889 
S4 MESH.EXACT.EXPLODE("Brain -- abnormalities") OR MESH.EXACT("Brain -- 
pathology") OR MESH.EXACT("Brain -- physiopathology") OR 
MESH.EXACT("Brain -- growth & development") OR MESH.EXACT("Brain 
Damage, Chronic") OR MESH.EXACT("Brain Injury, Chronic") OR 
MESH.EXACT("Brain Injuries") OR MESH.EXACT("Brain -- injuries") OR 
MESH.EXACT.EXPLODE("Cerebral Hemorrhage") OR 
MESH.EXACT("Intracranial Hemorrhages") OR MESH.EXACT("Intracranial 
Hemorrhage, Traumatic") OR MESH.EXACT.EXPLODE("Brain Hemorrhage, 
Traumatic") OR MESH.EXACT.EXPLODE("Subarachnoid Hemorrhage") 
223671 
S3 ti,ab(congenital* near/3 (heart or cardiac)) or ti,ab((heart or cardiac) near/3 
defect*) or ti,ab((heart or cardiac) near/3 abnormalit*) or ti,ab((heart or cardiac) 
near/3 malform*) or ti,ab((heart or cardiac) near/3 (anomaly or anomalies)) or 
ti,ab((aortic or aorta) near/3 coarct*) or ti,ab(transpos[*6] near/3 (arteries or 
artery or vessel[*1])) or ti,ab(double near/3 outlet near/3 ventricle[*1]) or 
ti,ab(heart near/3 hypoplas*) or ti,ab((septal or septum) near/3 defect*) or 
ti,ab(paten[*2] near/3 ductus near/3 arteriosus) or ti,ab(fallot[*1] near/3 (tetralogy 
or trilogy)) or ti,ab(cyanotic near/3 (heart or cardiac)) 
209511 
S2 EMB.EXACT.EXPLODE("congenital heart malformation") OR 
EMB.EXACT.EXPLODE("congenital heart disease") OR 
EMB.EXACT.EXPLODE("heart disease -- congenital disorder") OR 
EMB.EXACT("aorta coarctation") OR EMB.EXACT.EXPLODE("great vessels 
transposition") 
162526 
S1 MESH.EXACT.EXPLODE("Heart Defects, Congenital") OR 
MESH.EXACT.EXPLODE("Heart Diseases -- congenital") 
124348 
 
 
Databases: 
• The Cochrane Database of Systematic Reviews (CDSR, Cochrane Reviews: Issue 11 of 12, 
November 2014) (2 references) 
• Database of Abstracts of Reviews of Effects (DARE, Other Reviews: Issue 4 of 4, October 
2014) (0 references) 
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• The Cochrane Central Register of Controlled Trials (CENTRAL, Trials: Issue 10 of 12, 
October 2014) (16 references) 
• Health Technology Assessment Database (HTA, Technology Assessments: Issue 4 of 4, 
October 2014) (0 references) 
• NHS Economic Evaluation Database (NHS-EED, Economic Evaluations: Issue 4 of 4, 
October 2014) (0 references) 
 
ID Search  Hits 
#1 MeSH descriptor: [Heart Defects, Congenital] explode all trees 1541 
#2 MeSH descriptor: [Heart Diseases] explode all trees and with 
qualifiers: [Congenital - CN] 
22 
#3 (congenital* near/3 (heart or cardiac)):ti,ab,kw 880 
#4 ((heart or cardiac) near/3 defect*):ti,ab,kw 842 
#5 ((heart or cardiac) near/3 abnormalit*):ti,ab,kw 233 
#6 ((heart or cardiac) near/3 malform*):ti,ab,kw 33 
#7 ((heart or cardiac) near/3 (anomaly or anomalies)):ti,ab,kw 29 
#8 ((aortic or aorta) near/3 coarct*):ti,ab,kw 55 
#9 (transpos* near/3 (arteries or artery or vessel*)):ti,ab,kw 67 
#10 (double near/3 outlet near/3 ventricle*):ti,ab,kw 7 
#11 (heart near/3 hypoplas*):ti,ab,kw 57 
#12 ((septal or septum) near/3 defect*):ti,ab,kw 333 
#13 (paten* near/3 ductus near/3 arteriosus):ti,ab,kw 494 
#14 (fallot* near/3 (tetralogy or trilogy)):ti,ab,kw 105 
#15 (cyanotic near/3 (heart or cardiac)):ti,ab,kw 52 
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or 
#12 or #13 or #14 or #15 
2502 
#17 MeSH descriptor: [Brain] explode all trees and with qualifiers: 
[Abnormalities - AB] 
24 
#18 MeSH descriptor: [Brain] this term only and with qualifiers: 
[Pathology - PA] 
642 
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#19 MeSH descriptor: [Brain] this term only and with qualifiers: 
[Physiopathology - PP] 
654 
#20 MeSH descriptor: [Brain] this term only and with qualifiers: [Growth & 
development - GD] 
65 
#21 MeSH descriptor: [Brain Damage, Chronic] this term only 240 
#22 MeSH descriptor: [Brain Injury, Chronic] this term only 26 
#23 MeSH descriptor: [Brain Injuries] this term only 997 
#24 MeSH descriptor: [Cerebral Hemorrhage] explode all trees 684 
#25 MeSH descriptor: [Intracranial Hemorrhages] this term only 158 
#26 MeSH descriptor: [Intracranial Hemorrhage, Traumatic] this term only 13 
#27 MeSH descriptor: [Brain Hemorrhage, Traumatic] explode all trees 9 
#28 MeSH descriptor: [Subarachnoid Hemorrhage] explode all trees 454 
#29 ((brain* or cranial or cerebral or cerebell* or craniocerebral or 
intracerebral or intracranial) near/5 (malform* or abnormal* or 
anomaly or anomalies or defect* or dysfunction* or develop* or 
maturation* or maturity or impair* or delay* or function* or size or 
volume or growth or structur* or microstructur* or bleed* or 
microbleed* or hemorrhag* or microhemorrhag* or haemorrhag* or 
microhaemorrhag* or impedance or damage* or injury or injuries or 
trauma*)):ti,ab,kw 
10382 
#30 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 
or #27 or #28 or #29 
11446 
#31 #16 and #30 159 
#32 MeSH descriptor: [Fetal Monitoring] explode all trees 357 
#33 MeSH descriptor: [Fetal Heart] explode all trees 115 
#34 MeSH descriptor: [Fetus] explode all trees 1520 
#35 MeSH descriptor: [Fetal Diseases] this term only 177 
#36 MeSH descriptor: [Fetal Viability] this term only 7 
#37 MeSH descriptor: [Fetal Movement] this term only 62 
#38 MeSH descriptor: [Fetal Development] this term only 61 
#39 MeSH descriptor: [Fetal Weight] this term only 18 
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#40 MeSH descriptor: [Fetal Organ Maturity] this term only 42 
#41 MeSH descriptor: [Fetal Blood] this term only 543 
#42 MeSH descriptor: [Fetal Death] this term only 208 
#43 MeSH descriptor: [Fetal Resorption] this term only 1 
#44 MeSH descriptor: [Fetal Distress] this term only 128 
#45 MeSH descriptor: [Fetal Growth Retardation] this term only 273 
#46 MeSH descriptor: [Fetal Hypoxia] this term only 26 
#47 MeSH descriptor: [Fetal Mortality] this term only 6 
#48 MeSH descriptor: [Heart Rate, Fetal] this term only 317 
#49 MeSH descriptor: [Maternal-Fetal Exchange] this term only 314 
#50 MeSH descriptor: [Prenatal Diagnosis] explode all trees 936 
#51 MeSH descriptor: [Ultrasonography, Prenatal] explode all trees 494 
#52 MeSH descriptor: [Prenatal Exposure Delayed Effects] this term only 252 
#53 MeSH descriptor: [Prenatal Injuries] this term only 1 
#54 MeSH descriptor: [Prenatal Care] this term only 1062 
#55 MeSH descriptor: [Uterine Monitoring] this term only 17 
#56 MeSH descriptor: [Pregnancy] this term only 63 
#57 MeSH descriptor: [Pregnancy Complications] this term only 1161 
#58 MeSH descriptor: [Pregnancy Rate] this term only 1143 
#59 MeSH descriptor: [Pregnancy Trimesters] explode all trees 1473 
#60 MeSH descriptor: [Pregnancy, High-Risk] this term only 188 
#61 MeSH descriptor: [Pregnancy, Multiple] explode all trees 204 
#62 MeSH descriptor: [Pregnancy, Heterotopic] this term only 0 
#63 MeSH descriptor: [Pregnancy, Prolonged] this term only 113 
#64 MeSH descriptor: [Pregnancy, Ectopic] explode all trees 172 
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#65 MeSH descriptor: [Pregnant Women] this term only 97 
#66 MeSH descriptor: [Pregnancy, Unplanned] this term only 56 
#67 MeSH descriptor: [Pregnancy, Unwanted] this term only 43 
#68 (fetus* or foetus* or fetal* or foetal* or prenatal* or "pre natal*" or 
prepartal* or "pre partal*" or prepartum* or "pre partum*" or 
antenatal* or "ante natal*" or antepartal* or "ante partal*" or 
antepartum* or "ante partum*" or "in utero" or intrauterine or "intra 
uterine" or uterine or preimplant* or "pre implant*" or fetalis or foetalis 
or pregnan* or trimester*):ti,ab,kw 
34596 
#69 #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 
or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or 
#51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 
or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 
34773 
#83 #16 and #30 and #69 18 
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Table 1. Summary of the studies included which reported structural brain abnormalities in fetuses with Congenital Heart Defects 
(CHD). 
Author, 
year and 
origin 
Study 
Design 
CHD 
diagnosis
Gestational 
age at 
assessment 
(weeks) CHD (n) 
Assessment 
method Findings 
Data 
collection 
Mlczoch et 
al. 201322 Cohort 
Mixeda 
Range 20-37 
(mean 28) 53 MRI 
Total abnormalities: 39.6% (21/53) 
Austria Retrospective 
Malformations 7 (malformation of cortical 
development 3, agenesis of the corpus callosum 
2, holoprosencephaly 1, cerebellar hypoplasia 1), 
acquired lesions 5 (ventriculomegaly 1, ventricular 
bleeding 1, enlarged subarachnoidal spaces 1, 
germinolytic cysts 2) and asymmetric widening of 
ventricles and/or outer CSF spaces 9 (asymmetry 
of the ventricles 7, arachnoid cyst and enlarged 
cisterna magna 2).  
Brossard-
Racine et al. 
201424 Case-control 
Mixedb 
Range 18-39 
(mean 
30.61±4.67) 
144 
(194 
controls) MRI 
Total abnormalities: 22.9% (33/144) 
USA/Canada Prospective* 
Ventriculomegaly 13, increased extra-axial space 
10, vermian hypoplasia 3, periventricular cysts 2, 
white matter signal hyperintensity 2, cerebral 
cortical immaturity 3.                                          
The most common abnormalities were mild 
unilateral ventriculomegaly in 12/33 (36.4%) and 
increased extra-axial spaces in 10/33 (30.3%). 
Schellen et 
al. 201523 Case-control 
TOF 
Mean±SD: 
25.7±3.6 
weeks 
(median 
25.1) in 
cases and  
25.6±3.6 
weeks 
(median 
25.0) in the 
controls 
24 (24 
controls) MRI 
Total abnormalities: 21% (5/24) 
Austria Retrospective 
Ventriculomegaly was observed in 5 of 24 fetuses 
(21%) with TOF: bilateral mild ventriculomegaly 
was found in 3 of 24 fetuses (13%); unilateral mild 
ventriculomegaly was found in 1 of 24 fetuses 
(4%); and a combination of mild and moderate 
ventriculomegaly was found in another 1 of 24 
fetuses (4%). Ventriculomegaly occurred in none 
of the control fetuses. 
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CSF: cerebroplacental fluid; TOF: Tetralogy of Fallot; SD: standard deviation; MRI: magnetic resonance imaging. 
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Table 2. Summary of the studies included which reported changes in brain volume in fetuses with Congenital Heart Defects (CHD). 
Author, year 
and origin 
Study 
Design 
CHD 
diagnosis
Gestational 
age at 
assessment 
(weeks) 
CHD 
assessed
Assessment 
method Findings 
Data 
collection 
Limperopoulos 
et al. 201021 
USA/Canada 
Case-control 
Prospective Mixedc 
Range 25-37 
(median 30) 50 
3-D 
volumetric 
MRI Progressive decline in age-adjusted TBV and ICV. 
Schiessl et al. 
201133 
Germany 
Case-control 
Prospective Mixedf  14-38 39 
3D/4D 
ultrasound 
Brain volumes did not show a different growth 
pattern in fetuses with CHD when compared with 
the control group. 
Clouchoux et 
al. 2013††34 
USA/Canada 
Case-control 
Prospective HLHS 25.4 – 37.0 18 MRI 
Progressive third trimester fall-off in cortical gray 
and white matter volumes (P<0.001), and 
subcortical gray matter (P<0.05) in fetuses with 
HLHS. Significant delays in cortical gyrification 
were also evident in HLHS fetuses (P<0.001). In 
the HLHS fetus, local cortical folding delays were 
detected as early as 25 weeks in the frontal, 
parietal, calcarine, temporal, and collateral regions 
and appear to precede volumetric brain growth 
disturbances.  
Zeng et al. 
201546 
China 
Case-control 
Prospective Mixed 20-37 73 
3D 
ultrasound 
 After the 28th week global and regional brain 
volumes were progressively smaller in CHD 
relative to controls (p<0.05). The diagnostic 
category (P<0.001) was independently associated 
with smaller brain volumes in fetuses with CHD 
and the highest ratios occurred in cases of HLHS 
followed by aorta hypoplasia, TGA and TOF 
(P<0.001). 
Sun et al. 
201536 
Canada 
Case-control 
Prospective Mixed 
Mean±SD 
36±1 24** 
Phase 
contrast 
magnetic 
resonance 
and T2 
mapping 
 13% reduction in brain volume (P<0.001) or a full 
1-SD reduction in estimated brain weight Z score 
(P<0.001). 
Schellen et al. 
201523 
Austria 
Case-control 
Retrospective TOF 
Mean±SD: 
25.7±3.6 
(median 
25.1) in 24 MRI 
Mean TBV in fetuses with TOF was significantly 
lower than in normal control fetuses (difference of 
estimated means in TOF - controls = -13,874mm3, 
P <0.001), with reduced GMV (difference of 
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cases and  
25.6±3.6 
(median 
25.0) in 
controls 
estimated means in TOF - controls = -4242mm3, 
P=0.003) and SBV (difference of estimated means 
in TOF - controls = -9633, P=0.001).  Mean ICV 
was not significantly lower in cases (P=0.314). 
Mean VV was significantly higher (difference of 
estimated means in TOF - controls = 1962mm3, 
P=0.005) in fetuses with TOF; the lateral ventricles 
were, on average, significantly wider than in 
normal control fetuses (narrower lateral ventricle 
width, P=0.012; wider lateral ventricle width, 
P=0.023). Compared with normal control fetuses, 
fetuses with TOF exhibited greater eCSFV 
(difference of estimated means in TOF - controls = 
0.05, P <0.001) in relation to ICV. 
Masollar et al. 
2015*35† 
Spain 
Case-control 
Prospective Mixed 36-38 58 MRI 
Fetuses with CHD showed significantly smaller 
brain, intracranial and opercular volumes than 
controls. CHD fetuses presented significantly 
decreased depths for left and right parieto-
occipital, cingulate, and calcarine fissures 
compared with controls. Also observed a 
significantly increased depth of the left insular lobe 
with respect to controls. No differences were found 
in the right insula and Sylvian’s fissure depth 
between the two groups.  
** 3 fetuses with chromosomal abnormalities and 3 had associated abnormalities (excluded from this review); *† authors described 
the study as cohort, but includes controls (case-control); †† This study includes a subpopulation from the study by Limperopoulos et 
al. 2010; HLHS: hypoplastic left heart syndrome; TOF: Tetralogy of Fallot; TGA: transposition of the great arteries; SD: standard 
deviation; TBV: Total brain volume; GMV: Gray matter volume; SBV: subcortical brain volume; ICV: intracranial cavity volume; VV: 
ventricular volume; eCSFV: external cerebrospinal fluid volume; MRI: magnetic resonance imaging. 
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Table 3. Summary of the studies included which reported changes in brain metabolism/maturation in fetuses with Congenital Heart 
Defects (CHD). 
Author, year 
and origin 
Study 
Design CHD 
diagnosi
s 
Gestational 
age at 
assessment 
(weeks) 
CHD 
assessed 
Assessment 
method Findings 
Data 
collection 
Limperopoulos 
et al. 201021 
USA/Canada 
Case-
control 
Prospective Mixedc 
Range 25-37 
(median 30) 36 MRS 
N-acetylaspartate (NAA)/choline ratios increased in 
CHD fetuses, but were slower to rise. 
Sun et al. 
201536 
Canada 
Case-
control 
Prospective Mixed 
Mean±SD 
36±1 24** 
phase 
contrast 
magnetic 
resonance 
and T2 
mapping 
When the fetuses were compared to the controls, a 
mean 10% reduction in the oxygen saturation (SaO2) of 
blood supplied to the developing brain was found. 
Because there was no difference in cerebral blood 
flow, this resulted in an almost statistically significant 
15% reduction in cerebral oxygen delivery (DO2). Due 
to no difference in the extraction of oxygen by the 
brain, the result was a mean 32% reduction in cerebral 
oxygen consumption (VO2) in fetuses with CHD.  
Masollar et al. 
2015*35† 
Spain 
Case-
control 
Prospective Mixed 36-38 48 MRS 
Increased Inositol/Choline ratio in the frontal lobe and 
basal ganglia, decreased levels of NAA/Choline and 
Choline/Creatinine ratios also in both areas when 
compared with controls. A peak of lactate was 
identified in three CHD cases (one with critical aortic 
stenosis and hypoplastic left heart syndrome, one 
transposition of great vessels and one tricuspid atresia 
with hypoplastic right ventricle).  
** 3 fetuses with chromosomal abnormalities and 3 had associated abnormalities (excluded from this review); *† authors described 
the study as a cohort study, but has controls as well (case-control); MRS: magnetic resonance spectroscopy; SD: standard deviation. 
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Table 4. Summary of the studies included which reported changes in brain blood flow in fetuses with Congenital Heart Defects 
(CHD). 
Author, year 
and origin 
Study 
Design CHD 
diagnosi
s 
Gestational 
age at 
assessment 
in weeks 
CHD 
assessed 
Assessment 
method Findings 
Data 
collection 
Jouannic et al. 
200244 
France 
Case-
control 
Prospective TGA 36-38 23 
Doppler 
ultrasound 
The MCA PI in TGA was significantly lower than 
controls (median 1.37; range 1.10–2.02 vs 1.68; range 
1.46–2.04, p<0.001). No significant difference in the PI 
in the UA, the aorta and the ductus venosus Doppler 
between fetuses with TGA and controls. 
Donofrio et al. 
200341 
USA 
Case-
control 
Prospective 
 Mixed 
20 weeks to 
delivery 
(mean±SD 
26.5 ± 3.8) 36 
Doppler 
ultrasound 
Mean CPR was lower in fetuses with CHD compared to 
normal (mean±SD 1.09 ± 0.15 vs 1.16 ± 0.13, p<0.01), 
and mean cerebral artery RI was lower for fetuses with 
CHD compared to normal (0.79 ± 0.07 vs 0.84 ± 0.04, 
p<0.001). Mean umbilical artery RI was not different 
between the two groups (0.74 ± 0.10 vs 0.73 ± 0.07). 
Mean CPR in the subgroups according to the CHD 
diagnosis were: HLHS (1.05 ± 0.12, p<0.002), LVOTO 
(1.21 ± 0.20, p=NS), TGA (1.06 ± 0.08, p=0.07), TOF 
(1.11±0.19, p=NS), HRHS (1.09 ± 0.16, p=NS). The 
proportion of fetuses with abnormal CPR (< 1) were 5% 
(1) in normal fetuses compared to 44% (16) in fetuses 
with CHD (p<0.001), 58% in HLHS (7) (p<0.001), 0 in 
LVOTO (p=1), 25% (1) in TGA (p<0.30), 45% (5) in 
TOF (p<0.02), 60% (3) in HRHS (p<0.002). Mean MCA 
RI in the subgroups according to the CHD diagnosis 
were: HLHS (0.78 ± 0.07, p<0.001), LVOTO (0.80 ± 
0.02, p=NS), TGA (0.80 ± 0.07, p<0.05), TOF (0.78 ± 
0.07, p<0.001), HRHS (0.85 ± 0.07, p=NS). Mean UA 
RI in the subgroups according to the CHD diagnosis 
were: HLHS (0.75 ± 0.07, p=NS), LVOTO (0.67 ± 0.09, 
p=NS), TGA (0.75 ± 0.08, p=NS), TOF (0.73 ± 0.14, 
p=NS), HRHS (0.79 ± 0.08, p=NS). 
Kaltman et al. 
200543 
USA 
Case-
control 
Cross-
sectional Mixed 20-39 58 
Doppler 
ultrasound 
 Significant differences between z scores were seen in 
UA PI for right sided obstructive lesions (mean±SD 
0.65±1.33 vs -0.14±1.11, p=0.045) and MCA PI for 
HLHS (-1.22±1.58 vs -0.12±1.50, p=0.009) when 
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compared to controls. The U/C-PI ratio was not 
significantly different between groups (P=0.287). 
Modena et al. 
200642 
USA 
Case-
control 
Prospective Mixed 
mid-second 
trimester 71 
Doppler 
ultrasound 
No significant differences were found, between the 
CHD and the gestational age-matched controls group) 
in the mean values for MCA PI (mean±SD 2.03±0.47 
vs 2.08±0.43, p=0.518), UA PI (mean±SD 1.24±0.45 vs 
1.16±0.29, p=0.246), z score (mean±SD 0.43±1.93 vs 
0.64±1.76, p=0.515) and CPR (mean±SD 1.76±0.79 vs 
2.14±2.24, p=0.199). All abnormal (<5th centile) MCA 
PI were in fetuses with intra cardiac mixing lesions 
(5/71 vs 0/71, p=0.023). No significant differences were 
found, between the CHD and the gestational age-
matched controls group, in the CPR <5th centile (8/71 
vs 2/71, p=0.049) or UA PI >95th centile (6/71 vs 3/71, 
p=0.251). 
Chen et al. 
200837 
China 
Case-
control 
Prospective Ebsteins 23-37  11 
Doppler 
ultrasound 
Significant differences between cases and controls 
were seen in UA PI (p<0.005), MCA PI (p<0.001) and 
MCAPI/UAPI (p<0.001) 
Guorong et al. 
200938 
China 
Case-
control 
Prospective Mixed 20-40  45 
Doppler 
ultrasound 
 Significant differences between z scores of cases and 
controls were seen in UA PI (p=0.001) and UA PI/MCA 
PI (p<0.001). There was no significant difference in the 
MCA PI between fetuses with CHD (n = 45) and 
controls (n = 275), while fetuses with CHD complicated 
by congestive heart failure (n = 10) had a decreased 
MCA PI (p<0.001) compared to controls. 
Berg et al. 
200940 
Germany 
Case-
control 
Retrospecti
ve Mixed 19-41 113 
Doppler 
ultrasound 
Significant differences between z scores of cases and 
controls were seen for CPR (p<0.05). Differences were 
not significant for MCA PI or RI 
Itsukaichi et al. 
201139 
Japan 
Case-
control 
Retrospecti
ve Mixed 
range 28-34 
(median 30) 44 
Doppler 
ultrasound 
Statistically significant differences between cases and 
controls were seen in MCA RI <5th decile (25% vs 
7.1%, p=0.0025) and <10th decile (p=0.0016), UA RI 
>90th decile (22.7% vs 3.6%, p=0.0003) and MCA 
RI/UA RI <1 (11.4% vs 0, p=0.0007).  The percentages 
of fetuses showing MCA RI values <10th percentile 
(29.5% vs 8.6%, p=0.0016) and UA RI values >90th 
percentile were significantly higher in the CHD group 
than in the control group. 
Yamamoto et 
al. 201348 
Case-
control mixed 
third 
trimester 89 
Doppler 
ultrasound 
Lower MCA-PI, higher UA-PI and lower CPR were 
observed in HLHS and isolated coarctation with 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
Canada Retrospecti
ve 
(mean 32) reversed arch flow (n = 6) (P < 0.001) but not TGA, 
POTO or isolated coarctation with antegrade arch flow 
(n = 15) compared with controls. No difference was 
found between HLHS with anatomical coarctation and 
those without. 
Masollar et al. 
201447 
Spain 
Case-
control 
Prospective mixed 
median 22+3 
(range 20+0-
23+5) 95 
Doppler 
ultrasound 
 Fetuses with CHD showed significantly lower MCA-PI 
and CPR Z-scores (-0.23 vs 0.34 and -0.37 vs 0.30, 
respectively; both P < 0.001) and higher FMBV Z-
scores (2.35 vs 0.15; P < 0.001). FMBV > 95(th) 
percentile was observed in 81.1% of cases as 
compared with 10.5% in controls (P < 0.001). 
Zeng et al. 
201546 
China 
Case-
control 
Prospective Mixed 20-37 73 
3D 
ultrasound 
 MCA PI was lower in cases compared to controls 
(mean±SD 1.66±0.42 vs 1.77±0.35 p=0.04). 
Zeng et al. 
201545 
China 
Case-
control 
Prospective Mixed 
19+6-30+3 
(cases) and 
20+0 -30+7 
(controls) 112 
3D Power 
Doppler 
ultrasound 
 HLHS had significantly lower MCA-PI Z-scores than 
did the controls (mean±SD −2.01 ± 1.31 vs −0.63 ± 
0.77, P< 0.001). The MCA-PI Z-score was lower in 
fetuses with LSOL than in controls, but this difference 
did not reach the level of statistical significance (−1.04 
± 1.14 vs −0.63 ± 0.77, p=0.32). The MCA-PI Z-score 
did not differ between fetuses with RSOL and TGA and 
controls (P=0.90 and P=0.99, respectively). Total 
intracranial blood flow perfusion and perfusion of the 
territories of the three main arteries were significantly 
increased in the fetuses with HLHS compared with 
normal controls (all P < 0.001). Fetuses with LSOL also 
had significantly higher 3D power Doppler values than 
did controls (all P < 0.001). The blood flow perfusion 
indices in the ACA territory were significantly higher in 
the fetuses with TGA than in the controls (all P < 0.01).
There were no significant differences in 3D power 
Doppler indices between fetuses with RSOL and 
controls. In the fetuses with CHD, the increases in VI, 
FI and VFI relative to controls were highest in the ACA 
territory (P < 0.05). 
Sun et al. 
201536 
Canada 
Case-
control 
Prospective Mixed 
mean±SD 
36±1 24** 
phase 
contrast 
magnetic 
resonance 
and T2 
 When the fetuses were compared to the control, a 
mean 10% reduction in the oxygen saturation (SaO2) 
of blood supplied to the developing brain was found. 
Because there was no difference in cerebral blood flow, 
this resulted in an almost statistically significant 15% 
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mapping reduction in cerebral oxygen delivery (DO2). Due to no 
difference in the extraction of oxygen by the brain, the 
result was a mean 32% reduction in cerebral oxygen 
consumption (VO2) in fetuses with CHD. 
Masollar et al. 
2015‡‡ *†35 
Spain 
Case-
control 
Prospective mixed 20-24 58 
Doppler 
ultrasound 
 Fetuses with CHD showed significantly lower MCA-PI 
and CPR mean Z-score values, and significantly higher 
frontal FMBV Z-score values compared with controls. 
** 3 fetuses with chromosomal abnormalities and 3 had associated abnormalities (excluded from this review); ‡‡ study cohort might 
overlap with that of Masoller et al 2014; *† authors described the study as cohort, but has controls as well (case-control); TGA: 
transposition of the great arteries; MCA: middle cerebral artery; PI: pulsatility index; UA: umbilical artery; CPR: cerebroplacental ratio; 
RI: resistance index; HLHS: hypoplastic left heart syndrome; LVOTO: left ventricular outflow obstruction; TOF: Tetralogy of Fallot; 
HRHS: hypoplastic right heart syndrome; U/C: umbilical to cerebral ratio; POTO: pulmonary outflow tract obstruction; FMBV: LSOL: 
left-sided obstructive lesions; RSOL: right-sided obstructive lesions; fractional moving blood volume; VI: vascularization index; FI: 
flow index; VFI: vascularization flow index; ACA: anterior cerebral artery  
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Supplementary Table 1. Search strategy using Medline, Embase and The Cochrane 
Library (since inception) including The Cochrane Database of Systematic Reviews 
(CDSR), Database of Abstracts of Reviews of Effects (DARE) and The Cochrane 
Central Register of Controlled Trials (CENTRAL). 
Databases: Embase®,  Embase® Alert,  MEDLINE® 
 
Set# Searched for Results 
S15 s13 or s14 1719 
S14 ((s1 or s2 or s3) and (s4 or s5 or s6) and (s7 or s8 or s9 or s10 or s11)) not 
(animal(yes) or EMB.EXACT("nonhuman")) 
1537 
S13 (s1 or s2 or s3) and (s4 or s5 or s6) and (s7 or s8 or s9 or s10 or s11) and 
human(yes) 
1621 
S12 (s1 or s2 or s3) and (s4 or s5 or s6) and (s7 or s8 or s9 or s10 or s11) 1811 
S11 ti,ab(fetus[*2] or foetus[*2] or fetal[*2] or foetal[*2] or prenatal[*2] or "pre 
natal[*2]" or prepartal[*2] or "pre partal[*2]" or prepartum[*1] or "pre partum[*1]" 
or antenatal[*2] or "ante natal[*2]" or antepartal[*2] or "ante partal[*2]" or 
antepartum[*1] or "ante partum[*1]" or "in utero" or intrauterine or "intra uterine" 
or uterine or preimplant[*6] or "pre implant[*6]" or fetalis or foetalis or 
pregnan[*4] or trimester[*1]) 
1627149 
S10 EMB.EXACT("fetomaternal transfusion") OR EMB.EXACT("intrauterine growth 
retardation") OR EMB.EXACT.EXPLODE("prenatal diagnosis") OR 
EMB.EXACT("prenatal development") OR EMB.EXACT("prenatal stress") OR 
EMB.EXACT("prenatal injury") OR EMB.EXACT("prenatal disorder") OR 
EMB.EXACT("prenatal period") OR EMB.EXACT("prenatal drug exposure") OR 
EMB.EXACT("prenatal exposure") OR EMB.EXACT("prenatal growth") OR 
EMB.EXACT("prenatal mortality") OR EMB.EXACT("prenatal screening") OR 
EMB.EXACT("prenatal care") OR EMB.EXACT.EXPLODE("pregnancy") OR 
EMB.EXACT.EXPLODE("multiple pregnancy") OR EMB.EXACT("prolonged 
pregnancy") OR EMB.EXACT("pregnancy complication") OR EMB.EXACT("high 
risk pregnancy") OR EMB.EXACT.EXPLODE("ectopic pregnancy") OR 
EMB.EXACT("pregnancy disorder") OR EMB.EXACT("pregnancy outcome") OR 
EMB.EXACT("pregnancy rate") OR EMB.EXACT("early pregnancy factor") OR 
EMB.EXACT("pregnant woman") 
885654 
S9 EMB.EXACT("fetus") OR EMB.EXACT("fetus outcome") OR 
EMB.EXACT.EXPLODE("fetus maturity") OR EMB.EXACT.EXPLODE("fetus 
297644 
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development") OR EMB.EXACT("fetus hypoxia") OR EMB.EXACT("fetus 
disease") OR EMB.EXACT("fetus distress") OR EMB.EXACT("fetus 
malformation") OR EMB.EXACT.EXPLODE("fetus function test") OR 
EMB.EXACT.EXPLODE("fetus echography") OR EMB.EXACT.EXPLODE("fetus 
control") OR EMB.EXACT("fetus heart rate") OR EMB.EXACT("fetus 
monitoring") OR EMB.EXACT("fetus blood") OR EMB.EXACT("fetus heart") OR 
EMB.EXACT.EXPLODE("fetus (anatomy)") OR EMB.EXACT("fetus circulation") 
OR EMB.EXACT("fetus growth") OR EMB.EXACT("fetus mortality") OR 
EMB.EXACT("fetus movement") OR EMB.EXACT("fetus resorption") OR 
EMB.EXACT("fetus death") OR EMB.EXACT("fetus wastage") OR 
EMB.EXACT("fetus risk") OR EMB.EXACT("fetus weight") OR 
EMB.EXACT("fetal hemorrhage") OR EMB.EXACT("fetotoxicity") 
S8 MESH.EXACT.EXPLODE("Prenatal Diagnosis") OR 
MESH.EXACT.EXPLODE("Ultrasonography, Prenatal") OR 
MESH.EXACT("Prenatal Exposure Delayed Effects") OR 
MESH.EXACT("Prenatal Injuries") OR MESH.EXACT("Prenatal Care") OR 
MESH.EXACT("Uterine Monitoring") OR MESH.EXACT("Pregnancy") OR 
MESH.EXACT("Pregnancy Complications") OR MESH.EXACT("Pregnancy 
Rate") OR MESH.EXACT.EXPLODE("Pregnancy Trimesters") OR 
MESH.EXACT("Pregnancy, High-Risk") OR 
MESH.EXACT.EXPLODE("Pregnancy, Multiple") OR 
MESH.EXACT("Pregnancy, Heterotopic") OR MESH.EXACT("Pregnancy, 
Prolonged") OR MESH.EXACT.EXPLODE("Pregnancy, Ectopic") OR 
MESH.EXACT("Pregnant Women") OR MESH.EXACT("Pregnancy, 
Unplanned") OR MESH.EXACT("Pregnancy, Unwanted") 
715455 
S7 MESH.EXACT.EXPLODE("Fetal Monitoring") OR 
MESH.EXACT.EXPLODE("Fetal Heart") OR MESH.EXACT.EXPLODE("Fetus") 
OR MESH.EXACT("Fetal Diseases") OR MESH.EXACT("Fetal Viability") OR 
MESH.EXACT("Fetal Movement") OR MESH.EXACT("Fetal Development") OR 
MESH.EXACT("Fetal Weight") OR MESH.EXACT("Fetal Organ Maturity") OR 
MESH.EXACT("Fetal Blood") OR MESH.EXACT("Fetal Death") OR 
MESH.EXACT("Fetal Resorption") OR MESH.EXACT("Fetal Distress") OR 
MESH.EXACT("Fetal Growth Retardation") OR MESH.EXACT("Fetal Hypoxia") 
OR MESH.EXACT("Fetal Mortality") OR MESH.EXACT("Heart Rate, Fetal") OR 
MESH.EXACT("Maternal-Fetal Exchange") 
213787 
S6 ti,ab((brain* or cranial or cerebral or cerebell* or craniocerebral or intracerebral 
or intracranial) near/5 (malform* or abnormal* or anomaly or anomalies or 
defect* or dysfunction* or develop[*5] or maturation* or maturity or impair* or 
delay* or function* or size or volume or growth or structur[*2] or microstructur[*2] 
or bleed* or microbleed* or hemorrhag* or microhemorrhag* or haemorrhag* or 
721929 
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microhaemorrhag* or impedance or damage* or injury or injuries or trauma*)) 
S5 EMB.EXACT("brain malformation") OR EMB.EXACT("brain development") OR 
EMB.EXACT("nervous system development") OR EMB.EXACT("brain 
maturation") OR EMB.EXACT("brain dysfunction") OR EMB.EXACT("brain 
function") OR EMB.EXACT("brain size") OR EMB.EXACT("brain growth") OR 
EMB.EXACT.EXPLODE("brain metabolism") OR EMB.EXACT.EXPLODE("brain 
hemorrhage") OR EMB.EXACT("brain damage") OR EMB.EXACT("traumatic 
brain injury") OR EMB.EXACT("cerebellum injury") OR EMB.EXACT("brain 
injury") 
372889 
S4 MESH.EXACT.EXPLODE("Brain -- abnormalities") OR MESH.EXACT("Brain -- 
pathology") OR MESH.EXACT("Brain -- physiopathology") OR 
MESH.EXACT("Brain -- growth & development") OR MESH.EXACT("Brain 
Damage, Chronic") OR MESH.EXACT("Brain Injury, Chronic") OR 
MESH.EXACT("Brain Injuries") OR MESH.EXACT("Brain -- injuries") OR 
MESH.EXACT.EXPLODE("Cerebral Hemorrhage") OR 
MESH.EXACT("Intracranial Hemorrhages") OR MESH.EXACT("Intracranial 
Hemorrhage, Traumatic") OR MESH.EXACT.EXPLODE("Brain Hemorrhage, 
Traumatic") OR MESH.EXACT.EXPLODE("Subarachnoid Hemorrhage") 
223671 
S3 ti,ab(congenital* near/3 (heart or cardiac)) or ti,ab((heart or cardiac) near/3 
defect*) or ti,ab((heart or cardiac) near/3 abnormalit*) or ti,ab((heart or cardiac) 
near/3 malform*) or ti,ab((heart or cardiac) near/3 (anomaly or anomalies)) or 
ti,ab((aortic or aorta) near/3 coarct*) or ti,ab(transpos[*6] near/3 (arteries or 
artery or vessel[*1])) or ti,ab(double near/3 outlet near/3 ventricle[*1]) or 
ti,ab(heart near/3 hypoplas*) or ti,ab((septal or septum) near/3 defect*) or 
ti,ab(paten[*2] near/3 ductus near/3 arteriosus) or ti,ab(fallot[*1] near/3 (tetralogy 
or trilogy)) or ti,ab(cyanotic near/3 (heart or cardiac)) 
209511 
S2 EMB.EXACT.EXPLODE("congenital heart malformation") OR 
EMB.EXACT.EXPLODE("congenital heart disease") OR 
EMB.EXACT.EXPLODE("heart disease -- congenital disorder") OR 
EMB.EXACT("aorta coarctation") OR EMB.EXACT.EXPLODE("great vessels 
transposition") 
162526 
S1 MESH.EXACT.EXPLODE("Heart Defects, Congenital") OR 
MESH.EXACT.EXPLODE("Heart Diseases -- congenital") 
124348 
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Databases: 
• The Cochrane Database of Systematic Reviews (CDSR, Cochrane Reviews: Issue 11 of 12, 
November 2014) (2 references) 
• Database of Abstracts of Reviews of Effects (DARE, Other Reviews: Issue 4 of 4, October 
2014) (0 references) 
• The Cochrane Central Register of Controlled Trials (CENTRAL, Trials: Issue 10 of 12, 
October 2014) (16 references) 
• Health Technology Assessment Database (HTA, Technology Assessments: Issue 4 of 4, 
October 2014) (0 references) 
• NHS Economic Evaluation Database (NHS-EED, Economic Evaluations: Issue 4 of 4, 
October 2014) (0 references) 
 
ID Search  Hits 
#1 MeSH descriptor: [Heart Defects, Congenital] explode all trees 1541 
#2 MeSH descriptor: [Heart Diseases] explode all trees and with 
qualifiers: [Congenital - CN] 
22 
#3 (congenital* near/3 (heart or cardiac)):ti,ab,kw 880 
#4 ((heart or cardiac) near/3 defect*):ti,ab,kw 842 
#5 ((heart or cardiac) near/3 abnormalit*):ti,ab,kw 233 
#6 ((heart or cardiac) near/3 malform*):ti,ab,kw 33 
#7 ((heart or cardiac) near/3 (anomaly or anomalies)):ti,ab,kw 29 
#8 ((aortic or aorta) near/3 coarct*):ti,ab,kw 55 
#9 (transpos* near/3 (arteries or artery or vessel*)):ti,ab,kw 67 
#10 (double near/3 outlet near/3 ventricle*):ti,ab,kw 7 
#11 (heart near/3 hypoplas*):ti,ab,kw 57 
#12 ((septal or septum) near/3 defect*):ti,ab,kw 333 
#13 (paten* near/3 ductus near/3 arteriosus):ti,ab,kw 494 
#14 (fallot* near/3 (tetralogy or trilogy)):ti,ab,kw 105 
#15 (cyanotic near/3 (heart or cardiac)):ti,ab,kw 52 
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or 
#12 or #13 or #14 or #15 
2502 
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#17 MeSH descriptor: [Brain] explode all trees and with qualifiers: 
[Abnormalities - AB] 
24 
#18 MeSH descriptor: [Brain] this term only and with qualifiers: 
[Pathology - PA] 
642 
#19 MeSH descriptor: [Brain] this term only and with qualifiers: 
[Physiopathology - PP] 
654 
#20 MeSH descriptor: [Brain] this term only and with qualifiers: [Growth & 
development - GD] 
65 
#21 MeSH descriptor: [Brain Damage, Chronic] this term only 240 
#22 MeSH descriptor: [Brain Injury, Chronic] this term only 26 
#23 MeSH descriptor: [Brain Injuries] this term only 997 
#24 MeSH descriptor: [Cerebral Hemorrhage] explode all trees 684 
#25 MeSH descriptor: [Intracranial Hemorrhages] this term only 158 
#26 MeSH descriptor: [Intracranial Hemorrhage, Traumatic] this term only 13 
#27 MeSH descriptor: [Brain Hemorrhage, Traumatic] explode all trees 9 
#28 MeSH descriptor: [Subarachnoid Hemorrhage] explode all trees 454 
#29 ((brain* or cranial or cerebral or cerebell* or craniocerebral or 
intracerebral or intracranial) near/5 (malform* or abnormal* or 
anomaly or anomalies or defect* or dysfunction* or develop* or 
maturation* or maturity or impair* or delay* or function* or size or 
volume or growth or structur* or microstructur* or bleed* or 
microbleed* or hemorrhag* or microhemorrhag* or haemorrhag* or 
microhaemorrhag* or impedance or damage* or injury or injuries or 
trauma*)):ti,ab,kw 
10382 
#30 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 
or #27 or #28 or #29 
11446 
#31 #16 and #30 159 
#32 MeSH descriptor: [Fetal Monitoring] explode all trees 357 
#33 MeSH descriptor: [Fetal Heart] explode all trees 115 
#34 MeSH descriptor: [Fetus] explode all trees 1520 
#35 MeSH descriptor: [Fetal Diseases] this term only 177 
#36 MeSH descriptor: [Fetal Viability] this term only 7 
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#37 MeSH descriptor: [Fetal Movement] this term only 62 
#38 MeSH descriptor: [Fetal Development] this term only 61 
#39 MeSH descriptor: [Fetal Weight] this term only 18 
#40 MeSH descriptor: [Fetal Organ Maturity] this term only 42 
#41 MeSH descriptor: [Fetal Blood] this term only 543 
#42 MeSH descriptor: [Fetal Death] this term only 208 
#43 MeSH descriptor: [Fetal Resorption] this term only 1 
#44 MeSH descriptor: [Fetal Distress] this term only 128 
#45 MeSH descriptor: [Fetal Growth Retardation] this term only 273 
#46 MeSH descriptor: [Fetal Hypoxia] this term only 26 
#47 MeSH descriptor: [Fetal Mortality] this term only 6 
#48 MeSH descriptor: [Heart Rate, Fetal] this term only 317 
#49 MeSH descriptor: [Maternal-Fetal Exchange] this term only 314 
#50 MeSH descriptor: [Prenatal Diagnosis] explode all trees 936 
#51 MeSH descriptor: [Ultrasonography, Prenatal] explode all trees 494 
#52 MeSH descriptor: [Prenatal Exposure Delayed Effects] this term only 252 
#53 MeSH descriptor: [Prenatal Injuries] this term only 1 
#54 MeSH descriptor: [Prenatal Care] this term only 1062 
#55 MeSH descriptor: [Uterine Monitoring] this term only 17 
#56 MeSH descriptor: [Pregnancy] this term only 63 
#57 MeSH descriptor: [Pregnancy Complications] this term only 1161 
#58 MeSH descriptor: [Pregnancy Rate] this term only 1143 
#59 MeSH descriptor: [Pregnancy Trimesters] explode all trees 1473 
#60 MeSH descriptor: [Pregnancy, High-Risk] this term only 188 
#61 MeSH descriptor: [Pregnancy, Multiple] explode all trees 204 
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#62 MeSH descriptor: [Pregnancy, Heterotopic] this term only 0 
#63 MeSH descriptor: [Pregnancy, Prolonged] this term only 113 
#64 MeSH descriptor: [Pregnancy, Ectopic] explode all trees 172 
#65 MeSH descriptor: [Pregnant Women] this term only 97 
#66 MeSH descriptor: [Pregnancy, Unplanned] this term only 56 
#67 MeSH descriptor: [Pregnancy, Unwanted] this term only 43 
#68 (fetus* or foetus* or fetal* or foetal* or prenatal* or "pre natal*" or 
prepartal* or "pre partal*" or prepartum* or "pre partum*" or 
antenatal* or "ante natal*" or antepartal* or "ante partal*" or 
antepartum* or "ante partum*" or "in utero" or intrauterine or "intra 
uterine" or uterine or preimplant* or "pre implant*" or fetalis or foetalis 
or pregnan* or trimester*):ti,ab,kw 
34596 
#69 #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 
or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or 
#51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 
or #61 or #62 or #63 or #64 or #65 or #66 or #67 or #68 
34773 
#83 #16 and #30 and #69 18 
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Figure 1. Flow of study identification. CHD = congenital heart defects. 
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Figure 2. Pooled prevalence (forest plot) of structural brain abnormalities in fetuses with 
congenital heart defects.   
Each study is represented by a line. The box in the middle of the line represents the point effect 
estimate of this particular study. The midpoint of the box represents the point effect estimate, 
that is, the mean effect estimate for each study. The area of the box represents the weight given 
to the study. The diamond below the studies represents the overall estimate. The width of the 
line shows the confidence interval (CI) of the effect estimate of individual studies. The width of 
the diamond shows the CI for the overall effect estimate. N = total number in group, while n = 
number in group with the outcome. Heterogeneity (I2) = diversity between studies. 
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Figure 3. Pooled prevalence (forest plot) of structural brain abnormalities in fetuses with 
Tetralogy of Fallot. 
Each study is represented by a line. The box in the middle of the line represents the point effect 
estimate of this particular study. The midpoint of the box represents the point effect estimate, 
that is, the mean effect estimate for each study. The area of the box represents the weight given 
to the study. The diamond below the studies represents the overall estimate. The width of the 
line shows the confidence interval (CI) of the effect estimate of individual studies. The width of 
the diamond shows the CI for the overall effect estimate. N = total number in group, while n = 
number in group with the outcome. Heterogeneity (I2) = diversity between studies. 
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Figure 4. Quality criteria of the included articles, as assessed using the Strengthening the 
Reporting of Observational Studies in Epidemiology checklist. 
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